Emerging immunosuppressive drugs in myelodysplastic syndromes

Alteration of lipids and the transcription of lipid-related genes in myelodysplastic syndromes via a TP53-related pathway

(2012) Martin H. Ellis et al.   EXPERIMENTAL HEMATOLOGY

Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes

(2012) Rafael Bejar et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the Interleukin-6/Jak/Stat Pathway in Human Malignancies

(2012) Pasquale Sansone et al.   JOURNAL OF CLINICAL ONCOLOGY

Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management

(2011) Guillermo Garcia-Manero   AMERICAN JOURNAL OF HEMATOLOGY

Anti-TNF therapy

(2011) Nishanthi Thalayasingam et al.   BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY

Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries

(2011) C. R. Cogle et al.   BLOOD

Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies

(2011) R. V. Tiu et al.   BLOOD

Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy

(2011) Shikhar Aggarwal et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome

(2011) Jose Ramon Gonzalez-Porras et al.   CANCER

From MALT lymphoma to the CBM signalosome

(2011) Shaun Rosebeck et al.   CELL CYCLE

Mechanisms That Regulate Peripheral Immune Responses to Control Organ-Specific Autoimmunity

(2011) Gerard F. Hoyne   Clinical & Developmental Immunology

Blockade of Toll-like Receptor 2 Expression and Membrane Translocation in Rat Corneal Epithelial Cells by Glucocorticoid (TobraDex) After Penetrating Keratoplasty

(2011) Lang Bai et al.   CORNEA

IL-2 family cytokines: new insights into the complex roles of IL-2 as a broad regulator of T helper cell differentiation

(2011) Wei Liao et al.   CURRENT OPINION IN IMMUNOLOGY

New JAK2 inhibitors for myeloproliferative neoplasms

(2011) Alfonso Quintás-Cardama et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Corticosteroids shift the Toll-like receptor response pattern of primary-isolated murine liver cells from an inflammatory to an anti-inflammatory state

(2011) R. Broering et al.   INTERNATIONAL IMMUNOLOGY

TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression

(2011) Martin Jädersten et al.   JOURNAL OF CLINICAL ONCOLOGY

Glucocorticoids inhibit dendritic cell maturation induced by Toll-like receptor 7 and Toll-like receptor 8

(2011) Alexandre Larangé et al.   JOURNAL OF LEUKOCYTE BIOLOGY

How to manage lower-risk myelodysplastic syndromes

(2011) M A Sekeres   LEUKEMIA

Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes

(2011) Benjamin M. Craig et al.   LEUKEMIA RESEARCH

Horse versus Rabbit Antithymocyte Globulin in Acquired Aplastic Anemia

(2011) Phillip Scheinberg et al.   NEW ENGLAND JOURNAL OF MEDICINE

New Ways to Use DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndrome

(2011) S. D. Gore   Hematology-American Society of Hematology Education Program

What do we mean when we write “senescence,”“apoptosis,”“necrosis,” or “clearance of dying cells”?

(2010) Dror Mevorach et al.   Annals of the New York Academy of Sciences

Is the incidence of rheumatoid arthritis rising?: Results from Olmsted County, Minnesota, 1955-2007

(2010) Elena Myasoedova et al.   ARTHRITIS AND RHEUMATISM

Are we nearer to curing patients with MDS?

(2010) Mikkael A. Sekeres   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Th17 immune responses contribute to the pathophysiology of aplastic anemia

(2010) R. P. de Latour et al.   BLOOD

Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept

(2010) Bart L. Scott et al.   BRITISH JOURNAL OF HAEMATOLOGY

Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study

(2010) Bart L. Scott et al.   BRITISH JOURNAL OF HAEMATOLOGY

Vav1 couples the T cell receptor to cAMP response element activation via a PKC-dependent pathway

(2010) Dirk Haubert et al.   CELLULAR SIGNALLING

Extensive apoptosis of bone marrow cells as evaluated by the in situ end-labelling (ISEL) technique may be the basis for ineffective haematopoiesis in patients with myelodysplastic syndromes

(2010) Agapi Parcharidou et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Myelodysplastic Syndromes Classification and Risk Stratification

(2010) Rami S. Komrokji et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

The Genetic Basis of Myelodysplastic Syndromes

(2010) Rafael Bejar et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic Remissions

(2010) Elaine M. Sloand et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunosuppressive Therapy for Patients With Myelodysplastic Syndrome: A Prospective Randomized Multicenter Phase III Trial Comparing Antithymocyte Globulin Plus Cyclosporine With Best Supportive Care—SAKK 33/99

(2010) Jakob R. Passweg et al.   JOURNAL OF CLINICAL ONCOLOGY

Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion

(2010) Pierre Fenaux et al.   LEUKEMIA RESEARCH

The Rochester Epidemiology Project: exploiting the capabilities for population-based research in rheumatic diseases

(2010) H. M. Kremers et al.   RHEUMATOLOGY

Transmembrane TNF- : structure, function and interaction with anti-TNF agents

(2010) T. Horiuchi et al.   RHEUMATOLOGY

Treating inflammation with the Janus Kinase inhibitor CP-690,550

(2010) Lalitha Vijayakrishnan et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

JAK2V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms

(2010) Stephen T Oh et al.   Expert Review of Hematology

High-Risk Myelodysplastic Syndromes: Chemotherapy, Transplantation, and Beyond

(2010) Usama Gergis et al.   Current Hematologic Malignancy Reports

Pathogenic mechanisms in systemic lupus erythematosus

(2009) Andras Perl   AUTOIMMUNITY

Advancements in the molecular pathogenesis of myelodysplastic syndrome

(2009) Pearlie K Epling-Burnette et al.   CURRENT OPINION IN HEMATOLOGY

T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance

(2009) Robert J. Salmond et al.   IMMUNOLOGICAL REVIEWS

Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo

(2009) Charay Jennings et al.   Innate Immunity

Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

(2008) D. E. Rollison et al.   BLOOD

Aplastic anemia

(2008) Neal S Young et al.   CURRENT OPINION IN HEMATOLOGY

Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts

(2008) G. J. Mufti et al.   HAEMATOLOGICA

Factors Affecting Response and Survival in Patients With Myelodysplasia Treated With Immunosuppressive Therapy

(2008) Elaine M. Sloand et al.   JOURNAL OF CLINICAL ONCOLOGY

Th17 Cells and Rheumatoid Arthritis—From the Standpoint of Osteoclast Differentiation—

(2008) Kojiro Sato   ALLERGOLOGY INTERNATIONAL

Cell death recognition model for the immune system

(2007) Erwei Sun   MEDICAL HYPOTHESES